Inactive Instrument

Other languages OXiGENE Inc Nasdaq

Equities

US6918284042

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 12	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	Mar. 25
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22
Oncotelic Launches PDAO SEC chatbot	23-04-24
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology	23-04-19
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14
Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-13
Oncotelic Therapeutics, Inc Announces The Publication of High Intra-Tumor Transforming Growth Factor ?2 Level as A Predictor of Poor Treatment Outcomes in Pediatric Cancer of the Brainstem	23-03-13
Oncotelic Therapeutics, Inc. Announces Executive Changes	23-03-02
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer	23-02-06
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer	23-01-25
Oncotelic Therapeutics, Inc. Announces Launch of Wholly Owned Subsidiary, Pet2DAO Inc. and its Associated Token PDAO	23-01-17
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022	22-12-19
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18
Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric Gliomas	22-11-08
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma	22-05-25
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages OXiGENE Inc Nasdaq

Equities

US6918284042

Other languages

Filters